At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 180 enrolled
Drug / intervention
Anti- SARS-CoV-2 Plasma +1 morebiological
Likely dose
Anti- SARS-CoV-2 Plasma 1 unitfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Convalescent Plasma to Stem Coronavirus: A Randomized, Blinded Phase 2 Study Comparing the Efficacy and Safety Human Coronavirus Immune Plasma (HCIP) vs. Control (SARS-CoV-2 Non-immune Plasma) Among Adults Exposed to COVID-19
In Brief
A Phase 2 clinical trial evaluating Anti- SARS-CoV-2 Plasma and SARS-CoV-2 non-immune Plasma for Coronavirus and Convalescence. Completed, enrolled 180 participants across 25 sites.
Detailed Summary
Evaluate the efficacy of treatment with high-titer Anti- SARS-CoV-2 plasma versus control (SARS-CoV-2 non-immune plasma) in subjects exposed to Coronavirus disease (COVID-19) at day 28.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus, Convalescence
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartJun 2020
Primary CompletionApr 2021
Study CompletionJun 2021
TodayJul 2026
First PostedMar 27, 2020
Enrollment StartJun 10, 2020
Primary CompletionApr 22, 2021
Study CompletionJun 22, 2021
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 6.3 years ago
Interventions
Anti- SARS-CoV-2 Plasmabiological
SARS-CoV-2 convalescent plasma (1 unit; \~200-250 mL collected by pheresis from a volunteer who recovered from COVID-19 disease and has SARS-CoV-2 antibody titers ≥ 1:320
SARS-CoV-2 non-immune Plasmabiological
Normal human plasma collected prior to December 2019